UNSPSC 51261703: Nebivolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25F2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 030Y90569U, chemically known as 2h-1-benzopyran-2-methanol, alpha,alpha-(iminobis(methylene))bis(6-fluoro-3,4-dihydro- but generally known as nebivolol, which bears US NIH Compound Identifier 71301. European Medicines Agency schedules Nebivolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09175MIG.

UNSPSC 51261703 Nebivolol is a Commodity code that covers pharmaceutical products; recent state and local opportunities tagged to this code do not reflect nebivolol procurement but instead show acute demand for naloxone and direct-to-manufacturer pharmacy programs. State and local governments are using this code to source emergency medications and to redesign pharmacy benefit administration through direct contracting models that bypass traditional pharmacy benefit managers and wholesalers. The issuing bodies include county health departments and state health and human services commissions pursuing both immediate acquisition of lifesaving drugs and longer-term pharmacy supply-chain transformation.

Activity appears concentrated in Florida and Texas. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, under a two-year initial term with one-year renewal option, potentially funded through FEMA with compliance requirements for the Clean Air Act and Federal Water Pollution Control Act. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from vendors on direct contracting capacity with self-insured plans and state agencies, flexibility on negotiated net pricing without rebates, and experience implementing value-based agreements—a preliminary market-intelligence phase preceding a formal RFP. The code shows limited and geographically sparse recent activity; no other jurisdictions appear in the available opportunities block.